Qu Biologics is a Vancouver‑based, clinical‑stage biotechnology company established in 2007. They’ve pioneered a novel category of immunotherapies known as Site Specific Immunomodulators (SSIs) designed to harness and restore innate immune function in targeted tissues. Their pipeline includes two active Phase 2 clinical trials—RESILIENCE for adults aged 65+ and PERIOP‑06 in colorectal cancer—as well as ongoing data analysis in metabolic and oncology animal models (e.g. senescence reduction and synergy with CAR T‑cells).